CACNA1C gene polymorphisms, cardiovascular disease outcomes, and treatment response
about
Is personalized medicine achievable in obstetrics?Liver X receptor α gene polymorphisms and variable cardiovascular outcomes in patients treated with antihypertensive therapy: results from the INVEST-GENES study.Pharmacogenomics: application to the management of cardiovascular diseaseCardiovascular pharmacogenomicsA case for pharmacogenomics in management of cardiac arrhythmias.Autonomic and hemodynamic origins of pre-hypertension: central role of heredity.The role of genetics in pre-eclampsia and potential pharmacogenomic interventions.Genome-wide association study identifies pharmacogenomic loci linked with specific antihypertensive drug treatment and new-onset diabetes.Gene-environment interactions of selected pharmacogenes in arterial hypertension.An update on the pharmacogenetics of treating hypertension.CACNA1C polymorphisms Impact Cognitive Recovery in Patients with Bipolar Disorder in a Six-week Open-label Trial.Large-scale genome-wide analysis identifies genetic variants associated with cardiac structure and function.Association between CACNA1C gene polymorphisms and ritodrine-induced adverse events in preterm labor patients.Cardiovascular pharmacogenetics: a promise for genomically-guided therapy and personalized medicine.Voltage-gated calcium channels: Novel targets for cancer therapy.Does the bipolar disorder-associated CACNA1C gene confer susceptibility to schizophrenia in Han Chinese?A gain-of-function SNP in TRPC4 cation channel protects against myocardial infarction.
P2860
Q26864177-C3A8437B-75E3-4F69-910B-EFC62C45C64EQ34978296-84A0025D-366A-4BE1-B955-1313CECBFC01Q35309161-38064559-67D2-4D19-BB67-E6A1DAE55364Q35447163-4B350E11-31C8-4B6B-A9E4-4A1E014B8C2BQ35914690-052260D2-4364-410D-963F-9CBE0444042BQ36030841-71F8CC54-EB79-4129-AF26-0758FCD73CB5Q36441528-7E06573A-533C-4C2E-A2DC-327665047243Q37723155-5CD71BBB-FB44-48AB-8CF4-E2CE8A8B3704Q38066959-4BD0290A-15F3-496D-A32D-BAC51DAAEFB7Q38263731-0445A194-C053-41F7-B036-1428EABDA47EQ38647923-8052117F-FCB0-4B85-AFA7-087D6EAEB20CQ38732534-98063419-8242-4510-A128-E96CBA32E6D2Q38846045-9F7D38FD-9108-4D1A-979D-56899C9FEDE0Q38974781-13779883-9B61-4127-91E4-5AF17D600D77Q41145371-C8D47B3C-9766-4CC0-BA36-42197E43D6C7Q45906648-FEC2FA3B-745D-4074-8E10-65B87320EF52Q46373181-F70EBD7C-DA2B-4921-A5D3-4A912639827B
P2860
CACNA1C gene polymorphisms, cardiovascular disease outcomes, and treatment response
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
CACNA1C gene polymorphisms, cardiovascular disease outcomes, and treatment response
@en
CACNA1C gene polymorphisms, cardiovascular disease outcomes, and treatment response.
@nl
type
label
CACNA1C gene polymorphisms, cardiovascular disease outcomes, and treatment response
@en
CACNA1C gene polymorphisms, cardiovascular disease outcomes, and treatment response.
@nl
prefLabel
CACNA1C gene polymorphisms, cardiovascular disease outcomes, and treatment response
@en
CACNA1C gene polymorphisms, cardiovascular disease outcomes, and treatment response.
@nl
P2093
P2860
P1476
CACNA1C gene polymorphisms, cardiovascular disease outcomes, and treatment response
@en
P2093
Amber L Beitelshees
Carl J Pepine
Danxin Wang
Hrishikesh Navare
James I Moss
Julie A Johnson
Nicolas J Schork
Rhonda M Cooper-DeHoff
Taimour Y Langaee
P2860
P304
P356
10.1161/CIRCGENETICS.109.857839
P577
2009-06-03T00:00:00Z